Page last updated: 2024-11-05

sarkosyl

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth

Description

sarkosyl: RN given is for sarkosyl L, the parent cpd; structure [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID23668817
CHEMBL ID1903482
SCHEMBL ID23451
MeSH IDM0084357

Synonyms (78)

Synonym
gardol
maprosyl 30
137-16-6
sarcosyl nl
sarkosyl nl 100
sarkosyl nl 30
sodium lauroylsarcosine
compound 105
lauroylsarcosine sodium salt
sarkosyl nl 35
sarkosyl nl 97
sodium n-lauroylsarcosinate
n-lauroylsarcosine, sodium
nsc-117874
n-dodecanoyl-n-methylglycine, sodium salt
sarcosyl nl 30
medialan ll-99
n-lauroylsarcosine, sodium salt
sarkosyl nl
hamposyl l-30
sodium lauroylsarcosinate
sodium n-lauroylsarcosine
glycine, n-methyl-n-(1-oxododecyl)-, sodium salt
sodium [dodecanoyl(methyl)amino]acetate
sarcosine, n-lauroyl-, sodium salt
NCGC00164323-01
n-methyl-n-(1-oxododecyl)glycine, sodium salt
sodium lauroyl sarcosinate
nsc 117874
epa pesticide chemical code 000174
caswell no. 778b
einecs 205-281-5
n-dodecanoylsarcosine sodium salt
sodium n-dodecanoylsarcosinate
S0597
n-lauroylsarcosine sodium salt
sodium n-lauroyl sarcosinate
L0019
sarkosyl
unii-632gs99618
632gs99618 ,
glycine, n-methyl-n-(1-oxododecyl)-, sodium salt (1:1)
ec 205-281-5
tox21_202996
NCGC00260541-01
dtxsid0027066 ,
dtxcid907066
cas-137-16-6
n-dodecanoyl-n-methylglycine sodium salt
sodium n-dodecanoyl-n-methylglycinate
FT-0631797
AKOS015901704
sodium lauroyl sarcosinate [usp-rs]
sodium lauroyl sarcosinate [inci]
sodium lauroyl sarcosinate [ii]
n-methyl-n-(1-oxododecyl)glycine sodium salt (1:1)
medialan ll-33
sodium lauroyl sarcosinate [vandf]
gardol [mi]
SCHEMBL23451
W-108241
n-lauryl sarcosine sodium salt
CHEMBL1903482
mfcd00042728
sodium 2-(n-methyldodecanamido)acetate
Q309660
KSAVQLQVUXSOCR-UHFFFAOYSA-M
lauroylsarcosine (sodium)
sodium lauroyl sarcosine
A934513
lauroylsarcosine, sodium salt
STARBLD0009501
sodium;2-[dodecanoyl(methyl)amino]acetate
E81236
AS-81025
CS-0103267
HY-125920
lauroylsarcosine (sodium salt)

Research Excerpts

Pharmacokinetics

ExcerptReferenceRelevance
" The influence of hyperhydration on the serum and urinary pharmacokinetic (PK) profiles of rHuEPO was also investigated."( Hyperhydration Effect on Pharmacokinetic Parameters and Detection Sensitivity of Recombinant Human Erythropoietin in Urine and Serum Doping Control Analysis of Males.
Al-Maadheed, M; Athanasiadou, I; Dokoumetzidis, A; El Saftawy, W; Georgakopoulos, C; Valsami, G; Voss, SC, 2019
)
0.51

Compound-Compound Interactions

ExcerptReferenceRelevance
" We herein developed a quick detecting method using recombinase polymerase amplification (RPA) combined with lateral flow (LF) strip to detect DNA of Cryptosporidium oocysts in dairy cattle feces."( Recombinase polymerase amplification (RPA) combined with lateral flow (LF) strip for equipment-free detection of Cryptosporidium spp. oocysts in dairy cattle feces.
Ma, JG; Wang, M; Wu, YD; Xu, MJ; Zhang, LX; Zheng, WB; Zhou, DH; Zhu, XQ, 2016
)
0.43

Dosage Studied

ExcerptRelevanceReference
" Results practically identical to those previously published (Okayasu and Iliakis, 1989) were obtained, with a 1 h incubation at 60 degrees C during lysis with sodium-N-laurylsarcosine (NLS) resulting in almost linear dose-response curves."( The shape of DNA elution dose-response curves under non-denaturing conditions: the contribution of the degree of chromatin condensation.
Iliakis, G; Okayasu, R, 1992
)
0.28
" This increase in elution caused a reduction in the shoulder width of the DNA elution dose-response curve, but did not significantly affect the final slope."( Linear DNA elution dose response curves obtained in CHO cells with non-unwinding filter elution after appropriate selection of the lysis conditions.
Iliakis, G; Okayasu, R, 1989
)
0.28
"3 mL/g Volatile Suspended Solids (VSS) with dosage increasing from 0 (control) to 40 mg SLS/g TSS."( Enhancing methane production from anaerobic digestion of waste activated sludge with addition of sodium lauroyl sarcosinate.
Du, W; Huang, X; Li, X; Wang, D; Yang, Q; Zhang, J, 2021
)
0.62
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Protein Targets (6)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
AR proteinHomo sapiens (human)Potency22.38720.000221.22318,912.5098AID588516
estrogen nuclear receptor alphaHomo sapiens (human)Potency3.85790.000229.305416,493.5996AID743075
peroxisome proliferator-activated receptor deltaHomo sapiens (human)Potency44.66840.001024.504861.6448AID588534
vitamin D (1,25- dihydroxyvitamin D3) receptorHomo sapiens (human)Potency39.81070.023723.228263.5986AID588543
nuclear factor erythroid 2-related factor 2 isoform 1Homo sapiens (human)Potency68.58960.000627.21521,122.0200AID651741
Peroxisome proliferator-activated receptor alphaHomo sapiens (human)Potency39.81070.015823.527344.6684AID651778
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (50)

Processvia Protein(s)Taxonomy
negative regulation of cytokine production involved in inflammatory responsePeroxisome proliferator-activated receptor alphaHomo sapiens (human)
negative regulation of reactive oxygen species biosynthetic processPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
negative regulation of hepatocyte apoptotic processPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
negative regulation of signaling receptor activityPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
positive regulation of ATP biosynthetic processPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
negative regulation of transforming growth factor beta receptor signaling pathwayPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
negative regulation of phosphatidylinositol 3-kinase/protein kinase B signal transductionPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
positive regulation of transformation of host cell by virusPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
negative regulation of transcription by RNA polymerase IIPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
response to hypoxiaPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
gluconeogenesisPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
heart developmentPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
response to nutrientPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
epidermis developmentPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
cellular response to starvationPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
regulation of cellular ketone metabolic processPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
negative regulation of macrophage derived foam cell differentiationPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
negative regulation of cholesterol storagePeroxisome proliferator-activated receptor alphaHomo sapiens (human)
negative regulation of sequestering of triglyceridePeroxisome proliferator-activated receptor alphaHomo sapiens (human)
regulation of fatty acid metabolic processPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
intracellular receptor signaling pathwayPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
positive regulation of fatty acid beta-oxidationPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
negative regulation of appetitePeroxisome proliferator-activated receptor alphaHomo sapiens (human)
response to insulinPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
circadian regulation of gene expressionPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
behavioral response to nicotinePeroxisome proliferator-activated receptor alphaHomo sapiens (human)
wound healingPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
lipoprotein metabolic processPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
regulation of circadian rhythmPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
steroid hormone mediated signaling pathwayPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
response to ethanolPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
positive regulation of gluconeogenesisPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
negative regulation of blood pressurePeroxisome proliferator-activated receptor alphaHomo sapiens (human)
negative regulation of glycolytic processPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
positive regulation of DNA-templated transcriptionPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
positive regulation of transcription by RNA polymerase IIPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
nitric oxide metabolic processPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
positive regulation of fatty acid oxidationPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
positive regulation of lipid biosynthetic processPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
negative regulation of inflammatory responsePeroxisome proliferator-activated receptor alphaHomo sapiens (human)
negative regulation of cell growth involved in cardiac muscle cell developmentPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
enamel mineralizationPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
cellular response to fructose stimulusPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
negative regulation of miRNA transcriptionPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
negative regulation of leukocyte cell-cell adhesionPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
regulation of fatty acid transportPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
hormone-mediated signaling pathwayPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
fatty acid metabolic processPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
positive regulation of fatty acid metabolic processPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
cell differentiationPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (23)

Processvia Protein(s)Taxonomy
RNA polymerase II cis-regulatory region sequence-specific DNA bindingPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
DNA-binding transcription factor activity, RNA polymerase II-specificPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
DNA-binding transcription activator activityPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
transcription coactivator bindingPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
DNA-binding transcription repressor activity, RNA polymerase II-specificPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
DNA-binding transcription activator activity, RNA polymerase II-specificPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
DNA bindingPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
DNA-binding transcription factor activityPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
nuclear steroid receptor activityPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
nuclear receptor activityPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
protein bindingPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
zinc ion bindingPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
lipid bindingPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
phosphatase bindingPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
protein domain specific bindingPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
mitogen-activated protein kinase kinase kinase bindingPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
ubiquitin conjugating enzyme bindingPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
sequence-specific DNA bindingPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
protein-containing complex bindingPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
NFAT protein bindingPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
RNA polymerase II-specific DNA-binding transcription factor bindingPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
MDM2/MDM4 family protein bindingPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
DNA-binding transcription factor bindingPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (3)

Processvia Protein(s)Taxonomy
nucleusPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
nucleoplasmPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
chromatinPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
nucleusPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Research

Studies (272)

TimeframeStudies, This Drug (%)All Drugs %
pre-199060 (22.06)18.7374
1990's75 (27.57)18.2507
2000's61 (22.43)29.6817
2010's68 (25.00)24.3611
2020's8 (2.94)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials2 (0.72%)5.53%
Reviews2 (0.72%)6.00%
Case Studies3 (1.08%)4.05%
Observational0 (0.00%)0.25%
Other270 (97.47%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]